

Unexpected Binding Modes of Nitric Oxide Synthase Inhibitors Effective in the Prevention of a Cerebral Palsy Phenotype in an Animal Model [J. Am. Chem. Soc. 2010, 132, 5437–5442]. Silvia L Delker, Haitao Ji, Huiying Li, Joumana Jamal, Jianguo Fang, Fengtian Xue, Richard B. Silverman,\* and Thomas L. Poulos\*

Supporting Information. Figure S2 was mistakenly omitted.




Figure S2. Plots of the calculated binding free energy ( $\Delta G_{\text{calc}}$ ) vs the experimental binding free energy ( $\Delta G_{\text{exp}}$ ) using two different models. In panel A it is assumed that the aminopyridine carries a net +0.5 charge when the aminopyridine is oriented over the heme and a net +1.0 charge in the flipped orientation. In panel B the aminopyridine is assumed to carry a net +1.0 charge independent of orientation. The crystal structures used for the calculations were (3'5,4'5)-2 (eNOS and nNOS), (3'R,4'R)-2 (eNOS, nNOS, nNOS, nNOS, D597N/M366V, nNOS, D597N/M36V/Y706A), and (±)-N¹-{cis-4'-[(6''-amino-4''-methylpyridin-2''-yl)methylpyrrolidin-3'-yl}-N²-(4'-chlorobenzyl)ethane-1,2-diamine tetrahydrochloride (nNOS, eNOS).

JA107808U

10.1021/ja107808u Published on Web 09/21/2010